JPRN-jRCT2032220377进行中（未招募）Unknown
roLift System post-marketing surveillance
Kadono Yoshihiko0 个研究点目标入组 200 人开始时间: 2022年10月14日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Male
入选标准
- •Patients diagnosed with benign prostatic hyperplasia and with lower urinary tract symptoms (LUTS) who used this product according to IFU. Regardless of whether it is lateral or median lobe.
排除标准
- 未提供
研究者
相似试验
招募中
4 期
A post marketing study to evaluate safety and effectiveness of Remogliflozin and Remogliflozin-Metformin Combination in treatment of Diabetes patientsCTRI/2019/11/022062Glenmark Pharmaceuticals Ltd
招募中
不适用
Rezum System Post Market surveillancePatients with bothersome urinary symptoms associated with BPH.JPRN-UMIN000048675Boston Scientific Japan K.K.100
已完成
4 期
A post-marketing study of the marketed product Maxtra® P syrup for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031189Zuventus Healthcare Limited200
已完成
4 期
A post-marketing study of the marketed product Maxtra® P Tablets for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031390Zuventus Healthcare Limited200
进行中（未招募）
4 期
To collect safety data in patients with Wet-AMD after giving aflibercept injection in affected eye.CTRI/2017/12/010876Bayer Pharmaceutical Pvt Ltd